Moderate to severe psoriasis
Conditions
Interventions
Experimental group:Biologics combined with Benvermod cream
control group:Using IL-17A inhibitors alone
Sponsors
Shanghai Dermatology Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients with moderate to severe psoriasis who still have residual skin lesions (BSA = 10%) after 4 weeks of treatment with IL-17A inhibitors alone; (2) Women who are not pregnant and do not plan to conceive during the study period; (3) Fully understand the research content, voluntarily participate in the study, and have signed an informed consent form.
Exclusion criteria
Exclusion criteria: (1) Women during pregnancy or breastfeeding, or men/women preparing for pregnancy; (2) those who are known to be allergic to the active ingredient or excipients of the investigational drug; (3) Patients may not be able to complete the study for other reasons, or researchers may not consider it appropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area and severity of psoriasis in patients;PGA response rate (PGA0/1); | — |
Secondary
| Measure | Time frame |
|---|---|
| dermatology life quality index; | — |
Countries
China
Contacts
Public ContactDing Yangfeng
Shanghai Dermatology Hospital
Outcome results
None listed